Plasticell Delivers Protocols To Stemnion

Plasticell has successfully completed a collaboration with Stemnion, Inc., a Pittsburgh, PA-based biotechnology company focused on the applications of stem cells derived from human placentas. Plasticell used its flagship CombiCult technology to discover multiple novel, serum-free protocols that direct the differentiation of Stemnion’s stem cells into hard-to-obtain lineages. The protocols were ranked using Plasticell’s Ariadne bioinformatics software and subsequently validated by Stemnion scientists.
 
“Using CombiCult’s combinatorial technology, we identified several differentiation protocols for our cells at a fraction of the time, resources and cost compared to conventional trial-and-error methods,” said Randall Rupp, Stemnion’s vice president, Manufacturing and Development.
 
“This project once again demonstrates the flexibility and the power of CombiCult to push the differentiation of adult stem cells into various lineages,” said Dr. Lilian Hook, director of Research at Plasticell. “Stemnion provided us with a challenge that is typical of adult stem cell R&D programs, however this project was particularly interesting on several fronts, including, for the first time, utilizing placenta-derived stem cells as the starting cell-type.”